Transaction · 0001839882-25-011952

LEDERMAN SETH

LEDERMAN SETH, CEO, reported a transaction classified as grant at Tonix Pharmaceuticals Holding Corp. involving 123958.000000 shares for an estimated $0.00. Reported holdings after the transaction were 123958.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACEO
TNXPTonix Pharmaceuticals Holding Corp.
Filing timeFeb 27
Trade dateFeb 25, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
…
Pre-filing
…
Returns since
…

TNXP price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
TNXP since 2025-02-27Filed 553 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001839882-25-011952
Stock Option
Transaction date
Feb 25, 2025
Filed Feb 27, 2025, 11:48 PM · 2d delay
Shares
123k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
123k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Derivative Transaction Direct Ownership Large Holdings Increase
-6score
Filing-only score

-6

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Executive Officer

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Reporting person may be deemed to be a control person of this entity.

  2. F2

    Involuntary sale of fractional share following a reverse stock split of the Issuer's common stock.

  3. F3

    One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.

  4. F4

    The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.

Original filing · 0001839882-25-011952
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

TNXP